However, for those seeking a highly effective, less invasive option, semaglutide (Wegovy) offers a powerful medical alternative, providing a significant answer to the GLP1 weight loss vs surgery and diet question
December 2025 brought FDA approval for the oral version, designed for adults with obesity or overweight who also have at least one connected health issue
The SELECT trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% over a median 34.2 months in patients with overweight or obesity and pre-existing cardiovascular disease, independent of glycemic status [12]
This consensus-based guidance, which includes an outline of eight key nutritional priorities to support patients on GLP-1 medications, reflects the top interdisciplinary recommendations to help clinicians support patients receiving GLP-1 receptor agonists for obesity care with evidence-based nutritional and behavioral strategies
If you're struggling with nausea or other side effects on Ozempic, remember that proper nutrition can help
But most trials only last 6-12 months